In our pursuit of evaluating DDX3X as a therapeutic target in lung cancer, we conceived twelve potential heterobifunctional DDX3X degraders using Proteolysis Targeting Chimeras (PROTACs) technology [44], which leverage the ubiquitin-proteasome system to induce DDX3X degradation (Fig. 7A). This evidence concerns the gene DDX3X and lung carcinoma.